Pregabalin Capsule 75mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Ahngook Pharmaceutical Co., Ltd.
MFDS item code 202003840 · Approved 2020.05.26
This product's status changed to Expired on 2025.05.26. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also utilized as an adjunct for focal seizures in epilepsy patients, with or without secondary generalized symptoms. Additionally, it helps relieve symptoms of fibromyalgia. In summary, this medication is used for neuropathic pain, adjunctive treatment for focal seizures in epilepsy, and treatment of fibromyalgia.
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration method Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30 -<60: 75, 300, BID or TID ≥15 -<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the administration method. b: Supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Administration is not recommended in children under 12 years of age or in adolescent patients aged 12 ~17 years because sufficient safety and efficacy data are not available.
This medication may increase the risk of suicidal thoughts or actions; therefore, consult a healthcare professional immediately if mood changes or symptoms of depression appear during treatment. Do not take this medication if there is a history of hypersensitivity to it, or if there are certain genetic conditions such as lactose intolerance. Diabetic patients should be cautious as weight gain may require adjustments in the dosages of blood sugar control medications. If symptoms of angioedema, such as swelling around the face or mouth, occur, discontinue use immediately. Elderly patients may experience symptoms such as dizziness, drowsiness, or confusion, so extra caution is advised at the start of treatment. Blurred vision or changes in eyesight may occur, and these symptoms may improve upon discontinuation of the medication. Sudden discontinuation of this medication can result in withdrawal symptoms such as insomnia, headache, and anxiety; therefore, adjustments to the dosage should be made in consultation with a healthcare provider. Patients with a history of drug abuse should be closely monitored as there is a risk of abuse with this medication. Patients with heart disease or severe congestive heart failure should use this medication cautiously. Concomitant use with opioid analgesics may increase central nervous system depressant effects, so caution is needed. Patients with respiratory or renal disorders, and the elderly, have a higher risk of severe respiratory depression; therefore, dose adjustments may be necessary. In early pregnancy, there is a risk of fetal malformations, so it is recommended that pregnant women do not take this medication, and women of childbearing age should use effective contraception. Breastfeeding women should avoid nursing while taking this medication, as it may be transmitted through breast milk and affect the infant. Dizziness and drowsiness may occur when driving or operating machinery, so caution should be exercised until symptoms are confirmed post-dose. This medication can cause severe skin reactions, such as skin rash and Stevens-Johnson syndrome; if any skin abnormalities appear, discontinue use immediately and inform a healthcare professional. In cases of overdose, symptoms such as confusion, drowsiness, or seizures may occur; if necessary, treatments such as hemodialysis may be required. Keep this medication out of reach of children, and avoid transferring it to other containers as this can lead to a decrease in quality or accidents.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture; therefore, it should be stored in a tightly sealed container. The storage temperature should be maintained between 15 to 30 degrees Celsius at room temperature. Proper storage will help maintain the effectiveness of the medication for a longer period.
Hard capsule with a brown upper part and white lower part containing a white powder that is white or light yellow.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 75mg
Hard capsule · Prescription medication
Ahngook Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.